Heregulin-Dependent Delay in Mitotic Progression Requires HER4 and BRCA1

REFERENCES

• Abd El-Rehim, D. M., S. E. Pinder, C. E. Paish, J. A. Bell, R. S. Rampaul, R. W. Blamey, J. F. Robertson, R. I. Nicholson, and I. O. Ellis. 2004. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br. J. Cancer 91:1532–1542.
   PubMed Web of Science ®Google Scholar
• Alimandi, M., A. Romano, M. C. Curia, R. Muraro, P. Fedi, S. A. Aaronson, P. P. Di Fiore, and M. H. Kraus. 1995. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813–1821.
   PubMed Web of Science ®Google Scholar
• Altiok, S., D. Batt, N. Altiok, A. Papautsky, J. Downward, T. M. Roberts, and H. Avraham. 1999. Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-kinase/AKT in breast cancer cells. J. Biol. Chem. 274:32274–32278.
   PubMed Web of Science ®Google Scholar
• Arasada, R. R., and G. Carpenter. 2005. Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB-4 intracellular domain fragment. J. Biol. Chem. 280:30783–30787.
   PubMedGoogle Scholar
• Bobrow, L. G., R. R. Millis, L. C. Happerfield, and W. J. Gullick. 1997. c-erbB-3 protein expression in ductal carcinoma in situ of the breast. Eur. J. Cancer 33:1846–1850.
   PubMed Web of Science ®Google Scholar
• Brodie, S. G., X. Xu, W. Qiao, W. M. Li, L. Cao, and C. X. Deng. 2001. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 20:7514–7523.
   PubMed Web of Science ®Google Scholar
• Cao, L., W. Li, S. Kim, S. G. Brodie, and C. X. Deng. 2003. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev. 17:201–213.
   PubMed Web of Science ®Google Scholar
• Chen, Y., A. A. Farmer, C. F. Chen, D. C. Jones, P. L. Chen, and W. H. Lee. 1996. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res. 56:3168–3172.
   PubMed Web of Science ®Google Scholar
• Couch, F. J., M. L. DeShano, M. A. Blackwood, K. Calzone, J. Stopfer, L. Campeau, A. Ganguly, T. Rebbeck, and B. L. Weber. 1997. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N. Engl. J. Med. 336:1409–1415.
   PubMed Web of Science ®Google Scholar
• Eccles, S. A. 2001. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J. Mammary Gland Biol. Neoplasia 6:393–406.
   PubMed Web of Science ®Google Scholar
• Furuta, S., X. Jiang, B. Gu, E. Cheng, P. L. Chen, and W. H. Lee. 2005. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc. Natl. Acad. Sci. USA 102:9176–9181.
   PubMedGoogle Scholar
• Gudas, J. M., T. Li, H. Nguyen, D. Jensen, F. J. Rauscher III, and K. H. Cowan. 1996. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ. 7:717–723.
   PubMedGoogle Scholar
• Holbro, T., R. R. Beerli, F. Maurer, M. Koziczak, C. F. Barbas III, and N. E. Hynes. 2003. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100:8933–8938.
   PubMed Web of Science ®Google Scholar
• Holbro, T., and N. E. Hynes. 2004. ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 44:195–217.
   PubMed Web of Science ®Google Scholar
• Hynes, N. E., and H. A. Lane. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5:341–354.
   PubMed Web of Science ®Google Scholar
• Jones, F. E., T. Welte, X. Y. Fu, and D. F. Stern. 1999. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J. Cell Biol. 147:77–88.
   PubMed Web of Science ®Google Scholar
• Knowlden, J. M., J. M. Gee, L. T. Seery, L. Farrow, W. J. Gullick, I. O. Ellis, R. W. Blamey, J. F. Robertson, and R. I. Nicholson. 1998. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17:1949–1957.
   PubMed Web of Science ®Google Scholar
• Komuro, A., M. Nagai, N. E. Navin, and M. Sudol. 2003. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J. Biol. Chem. 278:33334–33341.
   PubMed Web of Science ®Google Scholar
• Lohrisch, C., and M. Piccart. 2001. HER2/neu as a predictive factor in breast cancer. Clin. Breast Cancer 2:129–135.
   PubMedGoogle Scholar
• Long, W., K. U. Wagner, K. C. Lloyd, N. Binart, J. M. Shillingford, L. Hennighausen, and F. E. Jones. 2003. Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development 130:5257–5268.
   PubMed Web of Science ®Google Scholar
• Marquis, S. T., J. V. Rajan, A. Wynshaw-Boris, J. Xu, G. Y. Yin, K. J. Abel, B. L. Weber, and L. A. Chodosh. 1995. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat. Genet. 11:17–26.
   PubMed Web of Science ®Google Scholar
• Miki, Y., J. Swensen, D. Shattuck-Eidens, P. A. Futreal, K. Harshman, S. Tavtigian, Q. Liu, C. Cochran, L. M. Bennett, W. Ding, et al. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71.
   PubMed Web of Science ®Google Scholar
• Naidu, R., M. Yadav, S. Nair, and M. K. Kutty. 1998. Expression of c-erbB3 protein in primary breast carcinomas. Br. J. Cancer 78:1385–1390.
   PubMed Web of Science ®Google Scholar
• Navolanic, P. M., L. S. Steelman, and J. A. McCubrey. 2003. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int. J. Oncol. 22:237–252.
   PubMed Web of Science ®Google Scholar
• Ni, C.-Y., M. P. Murphy, T. E. Golde, and G. Carpenter. 2001. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294:2179–2181.
   PubMed Web of Science ®Google Scholar
• Ohgaki, H., et al. 2004. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64:6892–6899.
   PubMed Web of Science ®Google Scholar
• Olayioye, M. A., R. M. Neve, H. A. Lane, and N. E. Hynes. 2000. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19:3159–3167.
   PubMed Web of Science ®Google Scholar
• Omerovic, J., E. M. Puggioni, S. Napoletano, V. Visco, R. Fraioli, L. Frati, A. Gulino, and M. Alimandi. 2004. Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp. Cell Res. 294:469–479.
   PubMedGoogle Scholar
• Pawlowski, V., F. Revillion, M. Hebbar, L. Hornez, and J. P. Peyrat. 2000. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res. 6:4217–4225.
   PubMed Web of Science ®Google Scholar
• Porter, L. A., and D. J. Donoghue. 2003. Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog. Cell Cycle Res. 5:335–347.
   PubMedGoogle Scholar
• Quinn, C. M., J. L. Ostrowski, S. A. Lane, D. P. Loney, J. Teasdale, and F. A. Benson. 1994. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology 25:247–252.
   PubMed Web of Science ®Google Scholar
• Rajan, J. V., M. Wang, S. T. Marquis, and L. A. Chodosh. 1996. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc. Natl. Acad. Sci. USA 93:13078–13083.
   PubMedGoogle Scholar
• Riese, D. J., and D. F. Stern. 1998. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20:41–48.
   PubMed Web of Science ®Google Scholar
• Sartor, C. I., H. Zhou, E. Kozlowska, K. Guttridge, E. Kawata, L. Caskey, J. Harrelson, N. Hynes, S. Ethier, B. Calvo, and H. S. Earp III. 2001. HER4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol. Cell. Biol. 21:4265–4275.
   PubMed Web of Science ®Google Scholar
• Schroeder, J. A., and D. C. Lee. 1998. Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland. Cell Growth Differ. 9:451–464.
   PubMedGoogle Scholar
• Sgagias, M. K., K. U. Wagner, B. Hamik, S. Stoeger, R. Spieker, L. J. Huber, L. A. Chodosh, and K. H. Cowan. 2004. Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle 3:1451–1456.
   PubMed Web of Science ®Google Scholar
• Slamon, D. J., et al. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182.
   PubMed Web of Science ®Google Scholar
• Srinivasan, R., C. E. Gillett, D. M. Barnes, and W. J. Gullick. 2000. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res. 60:1483–1487.
   PubMed Web of Science ®Google Scholar
• Stern, D. F. 2003. ErbBs in mammary development. Exp. Cell Res. 284:89–98.
   PubMed Web of Science ®Google Scholar
• Sunpaweravong, P., S. Sunpaweravong, P. Puttawibul, W. Mitarnun, C. Zeng, A. E. Baron, W. Franklin, S. Said, and M. Varella-Garcia. 2005. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 131:111–119.
   PubMed Web of Science ®Google Scholar
• Suo, Z., B. Risberg, M. G. Kalsson, et al. 2002. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J. Pathol. 196:17–25.
   Google Scholar
• Thompson, M. E., R. A. Jensen, P. S. Obermiller, D. L. Page, and J. T. Holt. 1995. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. 9:444–450.
   PubMed Web of Science ®Google Scholar
• Tidcombe, H., A. Jackson-Fisher, K. Mathers, D. F. Stern, M. Gassmann, and J. P. Golding. 2003. Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc. Natl. Acad. Sci. USA 100:8281–8286.
   PubMed Web of Science ®Google Scholar
• Tovey, S. M., C. J. Witton, J. M. Bartlett, P. D. Stanton, J. R. Reeves, and T. G. Cooke. 2004. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 6:R246–R251.
   PubMed Web of Science ®Google Scholar
• Troyer, K. L., and D. C. Lee. 2001. Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network. J. Mammary Gland Biol. Neoplasia 6:7–21.
   PubMed Web of Science ®Google Scholar
• Vaughn, J. P., P. L. Davis, M. D. Jarboe, G. Huper, A. C. Evans, R. W. Wiseman, A. Berchuck, J. D. Iglehart, P. A. Futreal, and J. R. Marks. 1996. BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ. 7:711–715.
   PubMedGoogle Scholar
• Vidal, G. A., A. Narres, L. Marrero, and F. E. Jones. 2005. Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. J. Biol. Chem. 280:19777–19783.
   PubMed Web of Science ®Google Scholar
• Vogt, U., K. Bielawski, C. M. Schlotter, U. Bosse, B. Falkiewicz, and A. J. Podhajska. 1998. Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. Gene 223:375–380.
   PubMedGoogle Scholar
• Wang, R. H., H. Yu, and C. X. Deng. 2004. A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc. Natl. Acad. Sci. USA 101:17108–17113.
   PubMed Web of Science ®Google Scholar
• Weaver, Z., C. Montagna, X. Xu, T. Howard, M. Gadina, S. G. Brodie, C. X. Deng, and T. Ried. 2002. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 21:5097–5107.
   PubMedGoogle Scholar
• Williams, C. C., J. G. Allison, G. A. Vidal, M. E. Burow, B. S. Beckman, L. Marrero, and F. E. Jones. 2004. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J. Cell Biol. 167:469–478.
   PubMedGoogle Scholar
• Wiseman, S. M., N. Makretsov, T. O. Nielsen, B. Gilks, E. Yorida, M. Cheang, D. Turbin, K. Gelmon, and D. G. Huntsman. 2005. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103:1770–1777.
   PubMed Web of Science ®Google Scholar
• Witton, C. J., J. R. Reeves, J. J. Going, T. G. Cooke, and J. M. Bartlett. 2003. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 200:290–297.
   PubMed Web of Science ®Google Scholar
• Xu, B., S.-T. Kim, and M. B. Kastan. 2001. Involvement of Brca1 in S-phase and G2-phase checkpoints after ionizing irradiation. Mol. Cell. Biol. 21:3445–3450.
   PubMed Web of Science ®Google Scholar
• Xu, X., Z. Weaver, S. P. Linke, C. Li, J. Gotay, X. W. Wang, C. C. Harris, T. Ried, and C. X. Deng. 1999. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3:389–395.
   PubMed Web of Science ®Google Scholar
• Yarden, Y., and M. X. Sliwkowski. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2:127–137.
   PubMed Web of Science ®Google Scholar
• Yu, W. H., J. F. Woessner, Jr., J. D. McNeish, and I. Stamenkovic. 2002. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. 16:307–323.
   PubMed Web of Science ®Google Scholar
• Zheng, L., S. Li, T. G. Boyer, and W. H. Lee. 2000. Lessons learned from BRCA1 and BRCA2. Oncogene 19:6159–6175.
   PubMedGoogle Scholar